Loading...
•
Sep 30, 2023
Compass Q3 2023 Earnings Report
Reported third quarter 2023 financial results with increased enrollment in Phase 2/3 study COMPANION-002 and FDA clearance of IND for CTX-8371.
Key Takeaways
Compass Therapeutics reported a net loss of $10.0 million for the third quarter of 2023, with R&D expenses at $8.8 million and G&A expenses at $3.1 million. The company's cash and marketable securities were $164 million as of September 30, 2023.
Enrollment in Phase 2/3 study COMPANION-002 increased due to opening clinical sites at large academic medical centers.
Initial data from the COMPANION-003 study in patients with advanced CRC is expected in the fourth quarter of this year.
FDA cleared the IND for CTX-8371, a PD-1 and PD-L1 bispecific antibody.
Cash and marketable securities were $164 million as of September 30, 2023, providing cash runway into 2026.